Improving anti-tumor efficacy of low-dose Vincristine in rhabdomyosarcoma via the combination therapy with FOXM1 inhibitor RCM1 is a research paper published in Frontiers in Oncology (2023). On theSindex it has a DataRank of 0. It has been cited 10 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Heart, Lung, and Blood Institute
Grant: HL132849, HL158659, HL141174, HL149631, HL152973
NHLBI NIH HHS
Grant: R01 HL132849
NHLBI NIH HHS
Grant: R01 HL158659
National Institutes of Health
Grant: 1R01HL132849-01
Targeting Foxm1 in pulmonary fibrosis
National Institutes of Health
Grant: 5R01HL141174-06
Transcriptional Regulation of Endothelial Cells after Neonatal Lung Injury
National Institutes of Health
Grant: 5R01HL152973-05
Development of novel therapeutic approaches for treatment of Alveolar Capillary Dysplasia
National Institutes of Health
Grant: 5R01HL149631-02
Molecular Mechanisms Regulated by FOXM1 in Chronic Lung Remodeling
National Institutes of Health
Grant: 5R01HL158659-02
Role of lung endothelial cells during fibrotic lung remodeling.
FWCI
0.92
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals